@prefix schema: .
@prefix gndo: .
@prefix lib: .
@prefix owl: .
@prefix xsd: .
@prefix skos: .
@prefix rdfs: .
@prefix editeur: .
@prefix geo: .
@prefix umbel: .
@prefix naf: .
@prefix sf: .
@prefix rdau: .
@prefix bflc: .
@prefix thesoz: .
@prefix dcterms: .
@prefix isbd: .
@prefix foaf: .
@prefix mesh: .
@prefix ram: .
@prefix mo: .
@prefix marcRole: .
@prefix agrelon: .
@prefix dcmitype: .
@prefix nsogg: .
@prefix dnbt: .
@prefix dbp: .
@prefix embne: .
@prefix rdf: .
@prefix dnb_intern: .
@prefix madsrdf: .
@prefix v: .
@prefix cidoc: .
@prefix dcatde: .
@prefix ebu: .
@prefix wdrs: .
@prefix bibo: .
@prefix gbv: .
@prefix agrovoc: .
@prefix lcsh: .
@prefix dc: .
a bibo:Issue;
dcterms:medium ;
rdau:P60049 ;
rdau:P60050 ;
rdau:P60048 ;
dc:identifier "(DE-101)1328807991";
umbel:isLike , ;
dc:identifier "(OCoLC)1562704062";
dcterms:language ;
a bibo:Article;
dc:title "Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL Registry";
marcRole:oth _:node1k0rmm5k0x33770308 .
_:node1k0rmm5k0x33770308 gndo:preferredName "Zaboras, Zygimantas";
owl:sameAs .
marcRole:oth _:node1k0rmm5k0x33770309 .
_:node1k0rmm5k0x33770309 gndo:preferredName "Jørgensen, Camilla Tøvik" .
marcRole:oth _:node1k0rmm5k0x33770310 .
_:node1k0rmm5k0x33770310 gndo:preferredName "Stensvold, Andreas" .
marcRole:oth _:node1k0rmm5k0x33770311 .
_:node1k0rmm5k0x33770311 gndo:preferredName "Pettersen, Heidi Hassel" .
marcRole:oth _:node1k0rmm5k0x33770312 .
_:node1k0rmm5k0x33770312 gndo:preferredName "Grdinic, Aleksandra Galovic" .
marcRole:oth _:node1k0rmm5k0x33770313 .
_:node1k0rmm5k0x33770313 gndo:preferredName "Brækkan, Sigrid Kufaas" .
marcRole:oth _:node1k0rmm5k0x33770314 .
_:node1k0rmm5k0x33770314 gndo:preferredName "Ghanima, Waleed" .
marcRole:oth _:node1k0rmm5k0x33770315 .
_:node1k0rmm5k0x33770315 gndo:preferredName "Tavoly, Mazdak" .
bibo:pageStart "e132";
bibo:pageEnd "e140";
dcterms:isPartOf ;
dcterms:description "Abstract: Background International guidelines are increasingly recommending direct oral anticoagulants (DOACs) as the first-line treatment for cancer-associated thrombosis (CAT). However, data regarding treatment patterns and adherence to guidelines in patients with CAT are scarce. Objectives This study aimed to explore anticoagulant treatment patterns in patients with CAT and to calculate the incidence rates of bleeding events. Methods Patients ≥18 years with active cancer and a first-time venous thromboembolism between 2005 and 2020 were identified through the Venous Thrombosis Registry in ØstfOLd HospitaL. Outcome measures were patterns of anticoagulant treatment during the study period and bleeding events. We calculated overall incidence rates per 100 person-years and 6- and 12-month cumulative incidence of major and clinically relevant nonmajor bleeding (CRNMB) during anticoagulant treatment. Results Median age of 842 CAT patients at the time of thrombosis was 69 years (interquartile range 61–77), and 443 (52.6%) were men. In total, 526 patients (62.5%) had pulmonary embolism and 255 (30.3%) had deep vein thrombosis. Low molecular weight heparin (LMWH) was prescribed to 713 (85.8%) patients, whereas 64 (7.7%) received DOACs and 54 (6.5%) received vitamin K antagonists as the initial anticoagulant treatment. Prescription of DOACs as initial treatment increased from 3.0% in 2013/2014 to 18.0% in 2019/2020. The incidence rate of major bleeding was 6.9 (95% confidence interval [CI] 5.2–9.2) and 10.1 (95% CI 8.0–12.9) in CRNMB. Conclusion Most patients were treated with LMWH. However, a gradual shift in treatment toward DOACs was observed. Overall, bleeding complications were rare and comparable to those reported in randomized trials."@de;
dcterms:license ;
dcterms:accessRights ;
wdrs:describedby .
dcterms:license ;
dcterms:modified "2024-05-10T07:20:49.000"^^xsd:dateTime .
dcterms:issued "2024";
bibo:issue "08.2024, 01";
owl:sameAs .